[1] 中华医学会内分泌学分会肝病与代谢学组. 中华医学会内分泌学分会“非酒精性脂肪性肝病与相关代谢紊乱诊疗共识” [J]. 中华内分泌代谢杂志, 2010, 26(7): 531
[2] Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference[J]. Hepatology, 2003, 37(5): 1202
[3] Kuo C F, Yu K H, Luo S F, et al. Gout and risk of nonalcoholic fatty liver disease[J]. Scand J Rheumatol, 2010, 39(6): 466
[4] Lee Y J, Lee H R, Lee J H, et al. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults[J]. Clin Chem Lab Med, 2010, 48(2): 175
[5] Johnson R J, Kang D H, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease[J]. Hypertension, 2003, 41(6): 1183
[6] Abdelmalek M F, Lazo M, Horska A, et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes[J]. Hepatology, 2012, 56(3): 952
[7] Lanaspa M A, Tapia E, Soto V, et al. Uric acid and fructose: potential biological mechanisms[J]. Semin Nephrol, 2011, 31(5): 426
[8] Lim J S, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(5): 251
[9] Marangella M. Uric acid elimination in the urine. Pathophysiological implications[J]. Contrib Nephrol, 2005, 147: 132
[10] Waring W S, Webb D J, Maxwell S R. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers[J]. J Cardiovasc Pharmacol, 2001, 38(3): 365
[11] Ames B N, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical- caused aging and cancer: a hypothesis[J]. Proc Natl Acad Sci U S A, 1981, 78(11): 6858
[12] Kang D H, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter[J]. Am J Nephrol, 2005, 25(5): 425
[13] Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J]. Diabetes, 2011, 60(4): 1258
[14] Xu C F, Yu C H, Xu L, et al. Hypouricemic therapy: a novel potential therapeutic option for nonalcoholic fatty liver disease[J]. Hepatology, 2010, 52(5): 1865
[15] Petta S, Camma C, Cabibi D, et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2011, 34(7): 757
[16] Loria P, Lonardo A, Carulli N. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver[J]. Hepatology, 2004, 39(6): 1748
[17] Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation[J]. Am J Gastroenterol, 2007, 102(12): 2708
[1]苏东峰,聂秀玲,孙丽荣.2型糖尿病合并高尿酸血症临床特征及相关危险因素分析[J].天津医科大学学报,2013,19(06):481.
[2]聂秀玲,宋林凌,孙丽荣.痛风患者血红蛋白水平与非酒精性脂肪性肝病关系的研究[J].天津医科大学学报,2020,26(06):533.
NIE Xiu-ling,SONG Lin-ling,SUN Li-Rong.Study on relationship between hemoglobin and gout combined with nonalcoholic fatty liver disease[J].Journal of Tianjin Medical University,2020,26(06):533.
[3]连宇航,余胡燕,田志霞,等.高尿酸血症对特发性膜性肾病患者肾小管萎缩/间质纤维化的预测价值[J].天津医科大学学报,2022,28(04):403.
LIAN Yu-Hang,YU Hu-Yan,TIAN Zhi-Xia,et al.Predictive value of hyperuricemia on tubular atrophy/interstitial fibrosis in patients with idiopathic membranous nephropathy[J].Journal of Tianjin Medical University,2022,28(06):403.